scans or other necessary tests, Petersen said. Some patients may also not have the financial means to cover the costs of the drug or the diagnostic tests, he added.
Despite these challenges, experts say the demand for Leqembi is likely to grow as more patients are diagnosed with early-stage Alzheimer’s and as the medical community gains more experience with the drug.
Meeks, the English professor, is optimistic about the future thanks to Leqembi. She plans to continue taking the drug and hopes to maintain her independence for as long as possible.
\”It’s not a cure, but it’s giving me time to live a normal life,\” Meeks said. \”I’m grateful for that.\”